Master formulation and compounding records

Records are kept only in this browser; nothing is sent to ClinDose. Export a file to move them. Sign in to also save to your account.

Ingredients

Ingredient chips: FDA 503A categories and lists, 21 CFR 216.24, and NIOSH hazardous drugs. Check an ingredient in detail, including FDA shortages.

Equipment
Compounding steps
Quality control

Beyond-use date

Current: 90 days · Duration supported by the cited stability study for this formula, container, and storage.

Work out the BUD
Preparation
Dosage form
Storage

Beyond-use date

14 days

Refrigerator

  • Nonpreserved aqueous dosage form: 14 days, refrigerated.
  • A nonpreserved aqueous CNSP must be stored in a refrigerator for this BUD.

USP <795> §10.4 (CNSPs requiring shorter BUDs), Table 4 (BUD limits by type of preparation)

Rules current as of the USP <795> and <797> revisions official November 1, 2023. Verify against the current official USP chapter before assigning a BUD.

References

Master formulation record: Gabapentin oral suspension 100 mg/mL

Oral suspension · Oral · Nonsterile (USP <795>) · Batch 100 mL

Ingredients

IngredientRoleQuantity
Gabapentinactive10 g
Oral Mix or Oral Mix SF suspending vehiclevehicle q.s.

Equipment

  • Class A prescription balance or electronic balance
  • Mortar and pestle
  • Graduated cylinder

Quality control

  • Visual inspection: uniform appearance, no foreign matter
  • Final volume or weight checked

Packaging, storage, and BUD

Container: Amber plastic bottles and amber plastic oral syringes · Storage: Controlled room temperature · BUD: 90 days

Basis: Duration supported by the cited stability study for this formula, container, and storage. Friciu M et al. PLoS One. 2017;12(4):e0175208. PMC5393583

Labeling

Shake well. Store as directed. Discard after the beyond-use date.

References

  1. Friciu M, Roullin VG, Leclair G. Stability of gabapentin in extemporaneously compounded oral suspensions. PLoS One. 2017;12(4):e0175208. PMC5393583. https://pmc.ncbi.nlm.nih.gov/articles/PMC5393583/

Notes

Crystallization occurred at 5 °C: do not refrigerate.

Prepared by
Approved by
Date

Record contents follow the master formulation and compounding record sections of USP <795> and <797>; check your state board's requirements. For licensed clinicians. Use with clinical judgment.